Pembrolizumab is also used in the first-line treatment of patients with metastatic, NSCLC, who do not have EGFR and ALK mutations and a level of neoplastic cells with PD-L1 expression in neoplastic tissue below 50% [37]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.